Outcome of Board Meeting

Ref: Syn/CS/SE/BM/2026-27/Jul/14 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India T +91 80 6891 9191 CIN: L85110KA1993PLC014937 www.syngeneintl.com July 29, 2026 To, To, The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Corporate Communication Department Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051 Scrip Code: 539268 Scrip Symbol: SYNGENE Sub: Outcome of the Board Meeting Dear Sir/Madam, Pursuant to Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors, at its meeting held today i.e. July 29, 2026, has inter-alia, considered and approved the Un-audited financial results (standalone and consolidated) as per Indian Accounting Standards (Ind-AS) for the quarter ended June 30, 2026. A copy of the unaudited financial results along with the Limited Review Reports is enclosed herewith. The Board Meeting commenced at 10:00 am (IST) and concluded at 03:31 pm (IST). The above information will also be made available on the website of the Company at www.syngeneintl.com. Kindly take the above information on record. Thanking You Yours faithfully, For SYNGENE INTERNATIONAL LIMITED Chethan Yogesh Company Secretary and Compliance Officer Encl: a/a SYNGENE INTERNATIONAL LIMITED CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 (Rs. in million, except per share data) Sl. No. Particulars 3 months ended Preceding Corresponding Previous year 30 June 2026 3 months ended 3 months ended in ended 31 March 2026 the previous year 31 March 2026 30 June 2025 (Unaudited) (Audited) (Unaudited) (Audited) (Refer Note 3) 1 Income a) Revenue from operations 6,630 9 ,600 7,993 34,238 b) Other Income 2 48 216 166 669 Total Income 6,878 9 ,816 8,159 34,907 2 Expenses a) Cost of chemicals, reagents and consumables consumed 1,585 2 ,022 2,230 8 ,243 b) Changes in inventories of finished goods and work-in-progress (48) 98 (219) 74 c) Employee benefits expense 2,070 2 ,485 2,126 9 ,045 d) Finance costs 41 65 5 9 260 e) Depreciation and amortisation expense [refer note 8] 9 56 953 946 3 ,871 f) Other expenses [refer note 9] 1,759 1 ,925 2,127 8 ,087 g) Foreign exchange fluctuation loss, net 4 80 227 4 8 643 Total expenses 6,843 7,775 7,317 3 0,223 3 Profit before tax and exceptional items (1-2) 35 2 ,041 842 4 ,684 4 Exceptional Items, net gain/ (loss) [refer note 10 & 11] (135) (74) - ( 732) 5 Profit before tax (3-4) ( 100) 1 ,967 8 42 3 ,952 6 Tax expense Current tax - 337 158 681 Deferred tax ( 79) 148 (56) 222 Total tax expense ( 79) 485 102 903 7 Profit for the period / year (5-6) ( 21) 1,482 7 40 3 ,049 8 Other comprehensive income (A) (i) Items that will not be reclassified to profit or (loss) ( 7) 11 2 (53) (ii) Income tax relating to items that will not be reclassified to profit or (loss) 2 (3) ( 1) 13 (B) (i) Items that will be reclassified to profit or (loss) 3 97 (1,340) 278 (3,027) (ii) Income tax relating to items that will be reclassified to profit or (loss) (113) 308 (85) 752 Other comprehensive income for the period / year, net of taxes 2 79 ( 1,024) 1 94 ( 2,315) 9 Total comprehensive income for the period / year (7+8) 2 58 4 58 9 34 7 34 10 Paid-up equity share capital (Face value of Rs.10 each) [refer note 5 & 6] 4 ,037 4 ,029 4 ,029 4 ,029 11 Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity' 43,009 12 Earnings per share (of Rs.10 each) (not annualised) (not annualised) (not annualised) (annualised) a) Basic (0.05) 3 .68 1.84 7.58 b) Diluted (0.05) 3 .68 1.83 7.57 See accompanying notes to the financial results SYNGENE INTERNATIONAL LIMITED CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 (Rs. in million, except per share data) Sl. No. Particulars 3 months ended Preceding Corresponding Previous year ended 30 June 2026 3 months ended 3 months ended in 31 March 2026 31 March 2026 the previous year 30 June 2025 (Unaudited) (Audited) (Unaudited) (Audited) (Refer Note 3) 1 Income a) Revenue from operations 7 ,360 10,365 8,745 3 7,387 b) Other Income 2 53 2 22 177 707 Total Income 7,613 1 0,587 8 ,922 3 8,094 2 Expenses a) Cost of chemicals, reagents and consumables consumed 1 ,782 2,233 2,395 9,112 b) Changes in inventories of finished goods and work-in-progress (48) 98 (219) 7 4 c) Employee benefits expense 2 ,591 3,008 2,617 1 1,049 d) Finance costs 96 1 21 116 488 e) Depreciation and amortisation expense [refer note 8] 1 ,122 1,115 1,112 4,529 f) Other expenses [refer note 9] 1 ,626 1,781 1,840 7,358 g) Foreign exchange fluctuation loss, net 5 01 2 11 4 8 609 Total expenses 7 ,670 8,567 7,909 33,219 3 Profit before tax and exceptional items (1-2) ( 57) 2 ,020 1 ,013 4 ,875 4 Exceptional Items, net gain/ (loss) [refer note 10 & 11] ( 135) (60) - ( 766) 5 Profit before tax (3-4) (192) 1 ,960 1,013 4,109 6 Tax expense Current tax 1 3 56 228 870 Deferred tax ( 103) 1 25 (82) 7 2 Total tax expense (102) 481 146 942 7 Profit for the period / year (5-6) (90) 1 ,479 867 3,167 8 Other comprehensive income (A) (i) Items that will not be reclassified to profit or (loss) (6) 1 3 3 (63) (ii) Income tax relating to items that will not be reclassified to profit or (loss) 2 ( 3) ( 1) 1 6 (B) (i) Items that will be reclassified to profit or (loss) 478 (1,180) 287 ( 2,679) (ii) Income tax relating to items that will be reclassified to profit or (loss) (121) 313 (75) 766 Other comprehensive income for the period / year, net of taxes 3 53 ( 857) 2 14 ( 1,960) 9 Total comprehensive income for the period / year (7+8) 2 63 6 22 1 ,081 1 ,207 10 Paid-up equity share capital (Face value of Rs.10 each) [refer note 5 & 6] 4,037 4,029 4,029 4,029 11 Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity' 44,362 12 Earnings per share (of Rs.10 each) (not annualised) (not annualised) (not annualised) (annualised) a) Basic (0.22) 3.68 2.16 7.87 b) Diluted (0.22) 3.67 2.15 7.87 See accompanying notes to the financial results SYNGENE INTERNATIONAL LIMITED Notes : 1 Thestatementofunauditedstandaloneandconsolidatedfinancialresults("theStatements")ofSyngeneInternationalLimited('the Company')forthequarterended30June2026havebeenreviewedbytheAuditCommitteeattheirmeetingheldon28July2026and approvedbytheBoardofDirectorsoftheCompanyattheirmeetingheldon29July2026.TheaboveStatementshavebeensubjectedto alimitedreviewbythestatutoryauditoroftheCompany.Thereportsofthestatutoryauditorareunqualified.TheStatementshavebeen preparedinaccordancewithIndianAccountingStandards(‘IndAS’)prescribedunderSection133oftheCompaniesAct,2013andin terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2 TheconsolidatedfinancialresultsincludethefinancialresultsoftheCompany-SyngeneInternationalLimited(includingitsemployee welfare trust) and the financial results of the following subsidiaries: i. Syngene USA Inc. ii. Syngene Scientific Solutions Limited iii. Syngene Manufacturing Solutions Limited (In the process of liquidation from 15 June 2026) The Company and the Subsidiaries are collectively referred to as 'the Group'. 3 Thestandaloneandconsolidatedfiguresforquarterended31March2026arethebalancingfiguresbetweenauditedfiguresinrespectof thefullfinancialyearandthepublishedunauditedyeartodatefiguresuptoendofthethirdquarterofthepreviousfinancialyearw [Showing first 8,000 characters — download PDF for full document]